In addition to state-of-the-art treatments, the physicians of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center conduct clinical trials through Yale Cancer Center or in the setting of multi-institutional studies coordinated by the national cancer consortia RTOG (Radiation Therapy Oncology Group) and ECOG (Eastern Cooperative Oncology Group).
Research that physicians of the program either conduct themselves or are involved with through affiliations with basic scientists at Yale University School of Medicine focuses on a better understanding of the mechanisms that lead to brain cancer and the translation of this knowledge into new treatment strategies.
Learn more about the program and its research
Investigators at the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center are known throughout the worldwide medical community for their ability to explore the biology of a cellular receptor called HER-2. Our medical oncologists have been particularly successful in developing treatment strategies for HER-2 positive breast cancer and are currently offering innovative therapies for all subtypes of breast cancer.
Learn more about the the program and its research
Yale Cancer Center continues to make innovative advances in the diagnosis and treatment of cutaneous lymphoma through the focused efforts of a ground-breaking clinical research team. Their multispecialty approach to the treatment of patients with cutaneous lymphomas has led to the development of FDA approved treatments that are now the standard of care worldwide.
Transimmunization, an innovation related to extracorporeal photochemotherapy (ECP) which was the first FDA approved selective immunotherapy for any cancer, is currently being investigated in clinical trials at Yale Cancer Center. As the scientific and clinical successor of extracorporeal photochemotherapy, it has potential to replace ECP as the standard of care for patients with advanced forms of cutaneous T-cell lymphoma.
Learn more about the Yale Hematology Program and its research
The Melanoma Program has one of only four NIH-funded Specialized Programs of Research Excellence (SPORE) grants in the country; these grants support research projects in melanoma. Also, the Milstein Meyer Center for Melanoma Research and Treatment is dedicated to developing more investigator- initiated clinical trials and designing new treatments for the often fatal illness.
Learn more about the Yale Cancer Center Melanoma Program and its research
Along with his leadership of the Yale Pediatric Hematology and Oncology Program, Gary Kupfer, MD is also a laboratory investigator who studies how cells normally maintain genome integrity as well as how defects in such a system can lead to cancer. In addition, the basic studies in the laboratory have lead to the potential for clinical applications, such as the identification of a new way to treat resistant cancers.
The lab works on the relationship of genomic instability and the propensity towards development of cancer. Specifically, it focuses on the genetic syndrome Fanconi anemia (FA). Children with FA are born with congenital anomalies and develop aplastic anemia and an assortment of leukemias and other cancers.
Learn more about the Yale Pediatric Hematology and Oncology Program and its research
Research efforts at the Center for Thoracic Cancers at Smilow Cancer Hospital and Yale Cancer Center span clinical research, basic and translational science and population sciences. These efforts include risk stratification and screening for lung cancer and molecular characterization of lung cancers.
Learn more about the program and its research
